Insufficient data collection

Drug-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. Data are limited regarding the safety and efficacy of Nobori (Biolimus A9 Eluting Stent) in primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Accordingly, the investigators will compare the outcomes of primary PCI for AMI between patients receiving Nobori versus uncoated stents.

Inclusion Criteria:

• age more than 20 years old
• chest pain lasting more than 20 min
• symptoms beginning within 12 hours before characterization
• electrocardiogram showing ST-segment elevation or new appearance of left bundle branch block
• increase in cardiac enzymes to more than 5-fold the normal laboratory values
• infarct-related vessel are anatomically suitable for percutaneous revascularization
• patients gave their signed, informed consent

Exclusion Criteria:

• previous stent implantation within 30 days
• allergy to any of the followings : aspirin, heparin, clopidogrel, biolimus A9 or its derivatives, stainless steel 316L, PLA (Poly-Lactic Acid) Polymer or its derivatives, and contrast media
• elective surgery scheduled within 6 months
• renal insufficiency with creatinine level of more than 2.5 mg/dL
• patients associated with bleeding and/or clotting disorders, and those refusing blood transfusion
• history of massive gastrointestinal or urinary tract bleeding within 6 months
• patients currently enrolled in other clinical trials
• pregnancy